News Sentiment

SLN sentiment intelligence

Silence Therapeutics PLC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 48 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 9.09 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 40

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-12.5% over one week, +35.9% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Silence Therapeutics rated speculative Buy on promising polycythemia vera drug with key Phase 2 data due 2026

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction -12.5% Price reacting lower
Trend fit Trend active 35.9% over four weeks
Fair value -14.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 31
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 40
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
TradingView 9
Investing.com 5
Stock Titan 4
simplywall.st 4
Investing.com South Africa 2
Insider Monkey 2
Investing.com Nigeria 2

Event Lens

What the news is about

Classified themes
Market update 22
Earnings 14
Analyst action 5
Regulatory and legal 4
Deals and strategy 1
Balance sheet 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-48 of 48
Business Wire Direct company coverage

Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

Silence Therapeutics presented follow-up data from its Phase 1 SANRECO study for divesiran, a potential best-in-class siRNA therapy for polycythemia vera (PV), at EHA 2026. The data showed durable reductions in phlebotomy use that persisted after the final dose, along with improv

Tone
Positive 71/100
Event
Market update
Published
11 Jun 2026 23:09
Source
Business Wire